“We are excited to move to our next stage of clinical development in subjects with moderately to severely active ulcerative colitis. G9A is a central hub on a gene network that was identified by the Athos AI2 platform through the integration of multi-omic and longitudinal clinical data from Athos’ IBD biorepository. The Athos drug development platform begins with over 25,000 high-quality patient samples sourced from premier global hospital systems. The AI2 platform includes the Athos data lake, singular well-established omics workflows, and an integrative deep machine learning engine. The company’s lead drug compound is ATH-063, an investigational, oral small molecule G9A inhibitor for inflammatory bowel disease.
